Menu
Recruiting NCT07040332

Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis

— Observational Allergic Bronchopulmonary Aspergillosis (ABPA)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Allergic Bronchopulmonary Aspergillosis (ABPA). Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and identify the biomarkers of typing, and to explore the clinical outcomes of different inflammatory phenotypes.

Interventions

  • Other
    No intervention

Primary outcome measures

  • Total serum IgE [Time frame: Up to 12 months]
Secondary outcome measures (2)
  • Aspergillus-specific IgE [Time frame: Up to 12 months]
  • Aspergillus-specific IgG [Time frame: Up to 12 months]

Eligibility criteria

Inclusion criteria

  • Meets the diagnostic criteria for allergic bronchopulmonary aspergillosis.
  • Meets the diagnostic criteria for fungal-sensitized asthma.

Exclusion criteria

  • Human immunodeficiency virus infection.
  • Malignant tumor.
  • Blood system disease.
  • autoimmune system disease.
  • History of pulmonary tuberculosis.
  • Patients with a history of smoking or still smoking.
  • Invasive pulmonary fungal disease.
  • Contraindications electronic bronchoscopy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Department of Respiratory, The First Affiliated Hospital of Shandong First Medical Univers — Jinan

Identifiers

NCT: NCT07040332 · QFS-2025-074

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗